Table 1 Baseline clinical characteristics of the orbits of patients with DON based on the treatment outcomea
Clinical characteristic | Total | Favorable | Unfavorable | Â |
|---|---|---|---|---|
n, (%) | n = 57 orbits | (29) | (28) | p-value |
Age – years (mean ± SD) | 50.75 (12.29) | 49.10 (11.49) | 52.46 (13.05) | 0.306 |
Sex – Female | 47 (82.5) | 22 (75.9) | 25 (89.3) | 0.297†|
Current use of Tobacco | 19 (33.3) | 11 (37.9) | 8 (28.6) | 0.454 |
BCVA – logMAR (mean ± SD) | 0.85 (0.63) | 0.61 (0.48) | 1.09 (0.67) | 0.003 |
Color vision test abnormal | ||||
 Abnormal | 41 (71.9) | 23 (79.3) | 18 (64.3) | 0.207 |
Disc morphology | ||||
 Normal | 32 (56.14) | 14 (48.28) | 18 (64.29) |  |
 Swelling | 18 (31.6) | 11 (37.9) | 7 (25) | 0.294 |
 Pale | 7 (12.3) | 4 (13.8) | 3 (10.7) | 1†|
Proptosis – mm (mean ± SD) | 20.55 (3.18) | 19.91(3.17) | 21.21 (3.1) | 0.123 |
IOP – mmHg (mean ± SD) | 18.61 (4.09) | 17.55 (3.74) | 19.71 (4.21) | 0.045 |
Visual field Defects in dB (median [IQR]) | −22.6 (−28; −16.4) | −23 (−28; −20) | − 22.25 (−29.25; −10.5) | 0.388‡ |
Biochemical and immunological characteristics | ||||
 TSH – mU/l (median [IQR]) | 0.06 (0.006–0.752) | 0.098 (0.005–0.845) | 0.035 (0.007–0.836) | 0.729‡ |
 FT4 – pmol/l (median [IQR]) | 1.51 (1.01–3.16) | 1.51 (1.01–3.72) | 1.48 (0.95–2.5) | 0.549‡ |
Thyroid status | ||||
 Euthyroid | 24 (42.1) | 13 (44.8) | 11 (39.3) | 0.672 |
 Hyperthyroidism | 28 (49.1) | 14 (48.3) | 14 (50) |  |
 Hypothyroidism | 5 (8.8) | 2 (6.9) | 3 (10.7) |  |
Type 2 diabetes mellitus | 22 (38.6) | 8 (27.6) | 14 (50) | 0.082 |
Time from onset to treatment in month (median [IQR]) | 1.3 (0.6–3.7) | 1.17 (0.55–3.47) | 1.3 (0.61–3.93) | 0.457‡ |
Mean follow-up time in month (mean ± SD) | 14.81 (4.06) | 13.91 (2.63) | 15.75 (5.03) | 0.088 |